Biopharma Companies With COVID-19 Treatments See $10 Billion Market in 2021
We expect quickly declining sales potential after that, however.
In the second of three articles, we assess the market for COVID-19 treatments. (Click here for our outlook for coronavirus vaccines and distribution.) The final article will cover prospects for the companies involved.
As with most viruses, developing COVID-19 treatments has been difficult, but several drugs have shown strong enough efficacy to gain regulatory support. Historically, one of the best ways to control viruses is through vaccines, and we believe the vaccines emerging will significantly lower the need for COVID-19 treatments by 2023 and beyond. Nevertheless, treatments are in high demand currently and are likely to remain so through 2021 and into 2022. Currently, several drugs are used to treat COVID-19, but most have limitations in efficacy and timing of use relative to the disease progression.
Damien Conover does not own shares in any of the securities mentioned above. Find out about Morningstar’s editorial policies.